How has your use of B-cell depleting therapy for MS changed during the COVID-19 pandemic?

Are there any specific patient populations that you are no longer routinely recommending to start B-cell depleting medications? For example, are you less likely to recommend B-cell depletion in older patients with progressive MS?

Answer from: at Academic Institution

There may be no "correct" answer to this question. In my practice, I have not altered my prescribing of B cell therapies. Although we have seen reduced antibody responses in MS patients on B cell therapies, this has not definitively been associated with a significantly increased risk of COVID infect...

Related Questions